comparemela.com

Tissue Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Amniotic Membrane Global Market Report 2023

Global Contact Lenses Marketplace 2023-2028: Soft Contact Lenses Continue to Dominate, Silicone Hydrogel (SiHy) Lenses Projected to Increase in Popularity

Ophthalmic Devices Technologies and Global Markets Report

Ophthalmic Device Global Market Report 2023: Launch of New Biocompatible Materials Bolsters Growth

TissueTech Receives FDA Clearance to Proceed with Phase 1 Clinical Study using Investigational New Drug TTAX03 to Treat Facet Joint Osteoarthritis Pain

TissueTech Receives FDA Clearance to Proceed with Phase 1 Clinical Study using Investigational New Drug TTAX03 to Treat Facet Joint Osteoarthritis Pain Investigators will evaluate the dosage and safety of Cryopreserved Amniotic Membrane and Cryopreserved Umbilical Cord TTAX03 for pain relief and functional improvement of facet joint osteoarthritis in the lumbosacral region News provided by Share this article Share this article MIAMI, March 8, 2021 /PRNewswire/ Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that its parent company TissueTech had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a dosing study using its Investigational New Drug (IND) TTAX03 to treat facet joint pain resulting from Osteoarthritis (OA). This Phase 1 randomized, double-blinded, placebo-controlled, dose-finding study will include a one-year follow-up to assess TT

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.